Download PDF
Exp Clin Endocrinol Diabetes 2008; 116: S64-S69
DOI: 10.1055/s-2008-1081490
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Association of Impaired Glucose Metabolism in Morbid Obesity with Hypoadiponectinaemia

S. Schinner 1 [*] , K. Kempf 2 [*] , H. Overmann 1 , H. S. Willenberg 1 , M. Schott 1 , B. Rose 2 , W. A. Scherbaum 1 , C. Herder 2
  • 1Department of Endocrinology, Diabetes and Rheumatology, University Hospital Düsseldorf, Germany
  • 2Institute for Clinical Diabetes Research, German Diabetes Centre, Leibniz Institute for Diabetes Research at Heinrich Heine University Düsseldorf, Germany
Further Information

Publication History

received 03.03.2008

accepted 07.04.2008

Publication Date:
05 September 2008 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Increased circulating levels of cytokines and chemokines and decreased adiponectin levels are associated with impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM). As obesity is the major risk factor for T2DM it is not clear why many patients with morbid obesity remain normoglycaemic and if this protection can be attributed to a lower grade of inflammation or higher adiponectin levels.

Materials and methods: Glucose tolerance of morbidly obese patients (n=2 754, body mass index ≥40 kg/m2) was assessed by oral glucose tolerance tests. In a case-control design we compared levels of eight immune mediators and adiponectin from patients with IGT/T2DM (n=52) and normal glucose tolerance (NGT; n=59). Gene expression in peripheral blood was determined by quantitative RT-PCR, and serum concentrations of immune mediators and adiponectin were measured by ELISA and bead-based multiplex technology.

Results: About 54% of the patients in our morbidly obese cohort were normoglycaemic, while 14% were diagnosed with IGT and 32% with T2DM. There was no statistically significant difference in mRNA expression or serum levels of proinflammatory markers. Interestingly, we could demonstrate an association of NGT with higher adiponectin levels (p=0.039). Adiponectin levels were negatively correlated with interleukin (IL)-6 and macrophage chemoattractant protein (MCP)-1, but independent the other immune mediators.

Conclusions: We found an association of lower adiponectin levels with IGT/T2DM, but no further increase in inflammatory markers in morbid obesity. This suggests that in addition to chronic, low-grade inflammation, adiponectin is an important factor in the development of, or protection against, T2DM in obesity.

Key words

adiponectin - inflammation - obesity - diabetes mellitus - peripheral blood

References

  • 1 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.  Lancet. 2005;  365 1415-1428
    CrossrefPubMedGoogle Scholar
  • 2 Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance.  Diabet Med. 2005;  22 674-682
    CrossrefPubMedGoogle Scholar
  • 3 Kopelman PG. Obesity as a medical problem.  Nature. 2000;  404 635-643
    CrossrefPubMedGoogle Scholar
  • 4 Hensrud DD, Klein S. Extreme obesity: a new medical crisis in the United States.  Mayo Clin Proc. 2006;  81 S5-S10
    PubMedGoogle Scholar
  • 5 Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women.  Ann Intern Med. 1995;  122 481-486
    PubMedGoogle Scholar
  • 6 Kempf K, Rose B, Herder C, Haastert B, Fusbahn-Laufenburg A, Reifferscheid A. et al . The metabolic syndrome sensitizes leukocytes for glucose-induced immune gene expression.  J Mol Med. 2007;  85 389-396
    CrossrefPubMedGoogle Scholar
  • 7 Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes.  Trends Immunol. 2004;  25 4-7
    CrossrefPubMedGoogle Scholar
  • 8 Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes?.  Diabetologia. 2005;  48 1038-1050
    CrossrefPubMedGoogle Scholar
  • 9 Cipolletta C, Ryan KE, Hanna EV, Trimble ER. Activation of peri-pheral blood CD14+monocytes occurs in diabetes.  Diabetes. 2005;  54 2779-2786
    CrossrefPubMedGoogle Scholar
  • 10 Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion.  J Clin Endocrinol Metab. 2007;  92 1023-1033
    CrossrefPubMedGoogle Scholar
  • 11 Weisberg SP, MacCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue.  J Clin Invest. 2003;  112 1796-1808
    CrossrefPubMedGoogle Scholar
  • 12 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ. et al . Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.  J Clin Invest. 2003;  112 1821-1830
    CrossrefPubMedGoogle Scholar
  • 13 Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R. et al . From blood monocytes to adipose tissue-resident macrophages: induc-tion of diapedesis by human mature adipocytes.  Diabetes. 2004;  53 1285-1292
    CrossrefPubMedGoogle Scholar
  • 14 Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS. et al . Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.  J Clin Endocrinol Metab. 1997;  82 4196-4200
    CrossrefPubMedGoogle Scholar
  • 15 Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity.  J Clin Endocrinol Metab. 1997;  82 1313-1316
    CrossrefPubMedGoogle Scholar
  • 16 Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion.  Obes Res. 2001;  9 414-417
    CrossrefPubMedGoogle Scholar
  • 17 Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B. et al . Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors.  Diabetologia. 2002;  45 805-812
    CrossrefPubMedGoogle Scholar
  • 18 Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.  JAMA. 2001;  286 327-334
    CrossrefPubMedGoogle Scholar
  • 19 Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE. et al . The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study.  Diabetes. 2001;  50 2384-2389
    CrossrefPubMedGoogle Scholar
  • 20 Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W. et al . Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.  Diabetes Care. 2007;  30 854-860
    CrossrefPubMedGoogle Scholar
  • 21 Esposito K, Pontillo A, Palo C Di, Giugliano G, Masella M, Marfella R. et al . Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.  JAMA. 2003;  289 1799-1804
    CrossrefPubMedGoogle Scholar
  • 22 Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M. et al . Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year.  Circulation. 2002;  105 804-809
    CrossrefPubMedGoogle Scholar
  • 23 Yener S, Demir T, Akinci B, Bayraktar F, Kebapcilar L, Ozcan MA. et al . Transforming growth factor-beta 1 levels in women with prior history of gestational diabetes mellitus.  Diabetes Res Clin Pract. 2007;  76 193-198
    CrossrefPubMedGoogle Scholar
  • 24 Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE. et al . Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters.  Int J Obes (Lond). 2006;  30 1347-1355
    CrossrefPubMedGoogle Scholar
  • 25 Maury E, Ehala-Aleksejev K, Guiot Y, Detry R, Vandenhooft A, Brichard SM. Adipokines oversecreted by omental adipose tissue in human obesity.  Am J Physiol Endocrinol Metab. 2007;  293 E656-E665
    CrossrefPubMedGoogle Scholar
  • 26 Herder C, Schneitler S, Rathmann W, Haastert B, Schneitler H, Winkler H. et al . Low-grade inflammation, obesity and insulin resistance in adolescents.  J Clin Endocrinol Metab. 2007;  92 4569-5474
    CrossrefPubMedGoogle Scholar
  • 27 Herder C, Haastert B, Muller-Scholze S, Koenig W, Thorand B, Holle R. et al . Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4).  Diabetes. 2005;  54 S11-S17
    CrossrefPubMedGoogle Scholar
  • 28 Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state.  Circulation. 2004;  110 1564-1571
    CrossrefPubMedGoogle Scholar
  • 29 Fogelstrand L, Hulthe J, Hulten LM, Wiklund O, Fagerberg B. Monocytic expression of CD14 and CD18, circulating adhesion molecules and inflammatory markers in women with diabetes mellitus and impaired glucose tolerance.  Diabetologia. 2004;  47 1948-1952
    CrossrefPubMedGoogle Scholar
  • 30 Sell H, Eckel J, Dietze-Schroeder D. Pathways leading to muscle insulin resistance – the muscle – fat connection.  Arch Physiol Biochem. 2006;  112 105-113
    CrossrefPubMedGoogle Scholar
  • 31 Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease.  Endocr Rev. 2006;  27 762-778
    CrossrefPubMedGoogle Scholar
  • 32 Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease.  Biochimie. 2004;  86 779-784
    CrossrefPubMedGoogle Scholar
  • 33 Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE. et al . Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.  J Clin Endocrinol Metab. 2001;  86 1930-1935
    CrossrefPubMedGoogle Scholar
  • 34 Kempf K, Hector J, Strate T, Schwarzloh B, Rose B, Herder C. et al . Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity.  Horm Metab Res. 2007;  39 595-600
    PubMedGoogle Scholar
  • 35 Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ.  Diabetes. 2006;  55 1537-1545
    CrossrefPubMedGoogle Scholar
  • 36 Herder C, Hauner H, Haastert B, Rohrig K, Koenig W, Kolb H. et al . Hypoadiponectinemia and proinflammatory state: two sides of the same coin?: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4).  Diabetes Care. 2006;  29 1626-1631
    CrossrefPubMedGoogle Scholar
  • 37 Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K. et al . PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.  Diabetes. 2001;  50 2094-2099
    CrossrefPubMedGoogle Scholar
  • 38 Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K. et al . The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.  Nat Med. 2001;  7 941-946
    CrossrefPubMedGoogle Scholar
  • 39 Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.  J Clin Invest. 2001;  108 1875-1881
    CrossrefPubMedGoogle Scholar
  • 40 Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S. et al . Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.  Nat Med. 2002;  8 1288-1295
    CrossrefPubMedGoogle Scholar
  • 41 American Diabetes Association. . Diagnosis and classification of diabetes mellitus.  Diabetes Care. 2006;  29 S43-S48
    PubMedGoogle Scholar
  • 42 Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system?.  Diabetologia. 1998;  41 1241-1248
    CrossrefPubMedGoogle Scholar
  • 43 Herder C, Baumert J, Thorand B, Koenig W, Jager W de, Meisinger C. et al . Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002.  Diabetologia. 2006;  49 921-929
    CrossrefPubMedGoogle Scholar
  • 44 Herder C, Kolb H, Koenig W, Haastert B, Muller-Scholze S, Rathmann W. et al . Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4).  Diabetes Care. 2006;  29 368-371
    CrossrefPubMedGoogle Scholar
  • 45 Herder C, Klopp N, Baumert J, Muller M, Khuseyinova N, Meisinger C. et al . Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002.  Diabetologia. 2008;  51 276-284
    CrossrefPubMedGoogle Scholar
  • 46 Rathmann W, Haastert B, Herder C, Hauner H, Koenig W, Meisinger C. et al . Differential association of adiponectin with cardiovascular risk markers in men and women. The KORA survey 2000.  Int J Obes (Lond). 2007;  31 770-776
    PubMedGoogle Scholar
  • 47 Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease.  Nat Clin Pract Gastroenterol Hepatol. 2007;  4 432-441
    CrossrefPubMedGoogle Scholar
  • 48 Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM. et al . Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study.  Diabetes Care. 2005;  28 1757-1762
    CrossrefPubMedGoogle Scholar
  • 49 Lee DH, Silventoinen K, Jacobs Jr DR, Jousilahti P, Tuomileto J. Gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women.  J Clin Endocrinol Metab. 2004;  89 5410-5414
    CrossrefPubMedGoogle Scholar
  • 50 Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y. et al . Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.  Circulation. 1999;  100 2473-2476
    CrossrefPubMedGoogle Scholar
  • 51 Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK. et al . IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies.  Diabetes. 2006;  55 2915-2921
    CrossrefPubMedGoogle Scholar
  • 52 Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?.  Diabetes. 2005;  54 ((Suppl 2)) S114-S124
    CrossrefPubMedGoogle Scholar
  • 53 Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle.  Endocrinology. 2006;  147 2458-2467
    CrossrefPubMedGoogle Scholar
  • 54 Sell H, Kaiser U, Eckel J. Expression of chemokine receptors in insulin-resistant human skeletal muscle cells.  Horm Metab Res. 2007;  39 244-249
    Article in Thieme ConnectPubMedGoogle Scholar

1 These authors contributed equally to the work.

Correspondence

Dr. S. Schinner

Department of Endocrinology

Diabetes and Rheumatology

University Hospital Düsseldorf

Moorenstraße 5

40225 Düsseldorf

Germany

Phone: +49/211/811 78 10

Fax: +49/211/811 78 60

Email: sven.schinner@uni-duesseldorf.de

      >